Page 15 - SLIDES

NABUCCO

Cohort 2

• High vs low dose ipilimumab + nivolumab
preop for MIBC

• NABUCCO Cohort 1 → MIBC patients
treated with Ipi/Nivo
• pCR 46%

• <pT2 58%

nd
• 2 cohort to optimize efficacy and
tolerability

• Also increase exposure to
nivolumab

• N=30 patients